Neurogene Inc.
NGNE | NASDAQ
$32.57
+$0.48 (+1.50%)
At close: Sep 21, 2026, 4:00 PM ET
$32.57
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Rachel L. McMinn | Founder, Executive Chair & Chief Executive Officer |
| Andrew E. Mulberg FAAP | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control |
| Arvind Sreedharan | Senior Vice President of Business Operations |
| Christina Shafer | Chief Commercial Officer |
| Christine Mikail Cvijic | President, CFO & Director |
| Donna Cochener-Metcalfe | Senior Vice President, General Counsel & Corporate Secretary |
| Julie Jordan | Chief Medical Officer |
| Lina Li | Executive Director of Investor Relations |
| Ricardo Jimenez | Senior Vice President of Technical Operations |
| Stuart Cobb | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 07, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 8-K | Current Report |
| Jul 02, 2026 | 424B5 | Filing |
| Jun 30, 2026 | 424B5 | Filing |
Neurogene Inc.
| Country | United States |
| IPO Date | Mar 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Rachel L. McMinn |
Contact Details
535 W 24th Street New York City,
New York 10011 United States
Stock Details
| Ticker Symbol | NGNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404644 |
| CUSIP Number | 64135M105 |
| ISIN Number | US64135M1053 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove NGNE